Jazz Pharmaceuticals has announced that its dopamine and norepinephrine reuptake inhibitor (DNRI) Sunosi (solriamfetol) has been approved by the FDA as a therapy to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnoea (OSA).
The authorisation covers doses of 75 mg and 150 mg in narcolepsy and 37.5 mg, 75 mg, and 150 mg in OSA, and marks the first approval of a dual-acting DNRI in this indication.
